HIPEC addition to SCS did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer patients. Both SCS alone and SCS with HIPEC groups exhibited similar safety profiles, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results